Mathias Sheila 4
4 · Virpax Pharmaceuticals, Inc. · Filed Jan 31, 2024
Insider Transaction Report
Form 4
Mathias Sheila
Chief Scientific Officer
Transactions
- Award
Stock Option (right to buy)
2024-01-29+112,000→ 112,000 totalExercise: $0.32Exp: 2034-01-28→ Common Stock (112,000 underlying)
Footnotes (1)
- [F1]These options vest pro rata on a month basis for 36 months commencing one year after the date of grant.